Sensitivity of canine hematological cancers to BH3 mimetics

BackgroundInhibition of antiapoptotic B-cell lymphoma 2 (BCL2) proteins by small molecule Bcl-2 homology 3 (BH3) mimetics causes rapid induction of apoptosis of human hematological cancers in vitro and in vivo. ObjectivesAssess in vitro sensitivity of non-neoplastic lymphocytes and primary hematological cancer cells from dogs to venetoclax (VEN) or the dual BCL2/ B-cell lymphoma-extra-large (BCLxL) inhibitor, navitoclax (NAV), and evaluate the association between BCL2 protein expression and VEN sensitivity. AnimalsNine client-owned dogs without cancer and 18 client-owned dogs with hematological cancer. MethodsProspective, nonrandomized noncontrolled study. Lymphocytes isolated from peripheral blood, lymph node, or bone marrow from dogs were incubated with BH3 mimetics for 24hours. Viable cells were counted using flow cytometry and half maximal effective concentration (EC50) was calculated. BCL2 protein from whole cell lysates was assessed via immunoblots. ResultsNodal B and T lymphocytes were more sensitive to VEN than circulating lymphocytes (P = .02). Neoplastic T lymphocytes were sensitive to VEN (mean EC50SD = 0.023 +/- 0.018 mu M), whereas most non-indolent B cell cancers were resistant to killing by VEN (mean EC50 +/- SD = 288 +/- 700 mu M). Unclassified leukemias showed variable sensitivity to VEN (mean EC50 +/- SD = 0.49 +/- 0.66 mu M). Detection of BCL2 protein was not associated with VEN sensitivity. Conclusion and Clinical ImportanceNeoplastic canine T lymphocytes are sensitive to VEN in vitro. Quantification of BCL2 protein alone is insufficient to predict sensitivity to VEN.

Automated summary

The study shows that malignant T lymphocytes in dogs are sensitive to venetoclax, but B-cell cancers have low sensitivity. Detection of BCL2 protein alone cannot predict the sensitivity to venetoclax.